TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07020221: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 616 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07020221 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07020221 Rescue Dossier →